In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. - Wikidata - awgldk - TriplyDB

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

http://www.wikidata.org/entity/Q39800142

about

Aptamers: A Feasible Technology in Cancer Immunotherapy Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer siRNA and RNAi optimization Targeting the tumor microenvironment: JAK-STAT3 signaling The Yin and Yang of Toll-like receptors in cancer Nanomedicine therapeutic approaches to overcome cancer drug resistance Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in Mice Aptamer-Mediated Targeted Delivery of Therapeutics: An Update Aptamers: A New Technological Platform in Cancer Immunotherapy Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Knocking down disease: a progress report on siRNA therapeutics Current prospects for RNA interference-based therapies Progress toward in vivo use of siRNAs-II Silencing disease genes in the laboratory and the clinic RNA Interference and Cancer Therapy STATs in cancer inflammation and immunity: a leading role for STAT3 S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM Aptamer-targeted cell-specific RNA interference Regulation and function of signal transducer and activator of transcription 3.Biocoder: A programming language for standardizing and automating biology protocols.CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles Rational design of immunostimulatory siRNAs.Eupolyphaga sinensis walker displays inhibition on hepatocellular carcinoma through regulating cell growth and metastasis signaling.HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop.Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity Applications of proteomic technologies for understanding the premature proteolysis of CFTR.Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway.TLR9 is critical for glioma stem cell maintenance and targeting.Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy.Efficient inhibition of intraperitoneal ovarian cancer growth in nude mice by liposomal delivery of short hairpin RNA against STAT3.Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer.Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease

P2860

Q26740303-70B9078F-62F8-4C19-9BF5-B8F9448B0634 Q26741623-999B2323-36F7-4BF4-96B2-6AD969AFBFBE Q26769738-4245D1AE-72A8-4F44-B723-91858E4BA06C Q26825658-3419107E-5EA3-46DE-A5F7-F50B33122098 Q26851526-C68A3858-51B6-4A55-A273-DAC1D818C723 Q27011692-0747C9D7-F793-4B29-BFB2-F3F39F4301AF Q27318732-CBDCC188-A6C8-432E-919D-E4F00466AA8A Q28066827-4475AECE-28BB-47D5-9E5E-C18C18E9197A Q28068981-6E18BF86-277F-4E38-BCF6-8F8E4804969D Q28080262-55A5E165-1440-46D0-81D1-4E7330A3F6AB Q28082939-D2A06163-9680-417F-B076-C9C8262D22D1 Q28235733-3D93657C-A7EC-4062-A653-18A81A639993 Q28255877-17E6E1FC-DCDA-4E31-8DC9-E53FB19DA270 Q29039090-D6971401-F2FC-4CA7-87E9-11CD28FC9E30 Q29392204-6D9E0409-AB11-47C0-BE51-D52FB6C87750 Q29547203-52908AA1-2140-4A86-9FDD-F4CF85DA8DE8 Q30514214-868B58A2-F51C-4B0E-8FAF-BB3396512048 Q31085777-D861643E-B819-419C-8D1B-FFA5C6D73A31 Q33553545-0FE0C39B-2B26-4488-8A71-E1BEFB330F3C Q33578030-23B16C0C-89D0-4485-9CB5-9008B91F151E Q33717239-843EDDE1-F7E2-4C73-AC62-1B7BDFDAFB1C Q33728856-DF676D9C-B785-409E-8CBD-71B47598F111 Q33741156-5B3B74CA-D838-4C9E-97FF-437FB33B932E Q33808334-271E3025-C1C4-4ED6-A95E-59237B363AD2 Q33811442-555EAC29-3129-467A-BF16-E6A3324E6237 Q33822185-FEE2192B-0AD7-42E0-BB76-A622CD0738F9 Q33827192-EC331198-8264-44E7-9507-2A004D22BC69 Q33906033-55B461FA-6F5C-431D-9ED5-0891C9601CAB Q33921803-993C23AB-B960-4505-A446-2B457EE98C48 Q33986439-E50EDB8B-F6D5-4E1B-84F3-C3EB1F19E64A Q34076025-01B8C663-1A2E-47F9-ADD3-EE5D23EF5D52 Q34154752-7E3632D7-2484-4C44-8C66-095D2D1B27D3 Q34204722-9D1594B7-9E47-4C98-A929-05C14D87A972 Q34313026-1975D783-0D82-4702-9E46-129E406F2D47 Q34320769-025BDB75-C3F6-44EA-B20A-AF938DCFAE94 Q34373036-89C21BB3-6274-4C13-8684-4D35404978C6 Q34419534-1E01135E-6A36-417C-A1AD-C99308D4EBC4 Q34473451-58440B25-2AFD-44A6-946E-04B8A07F49A3 Q34552079-280086BA-B7F5-40EB-AB0A-FE95CE3D8A8B Q34553476-4E9A9100-F434-4E91-8478-6F868C8016AC

P2860

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

http://www.wikidata.org/entity/Q39800142

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

In vivo delivery of siRNA to i ...... es antitumor immune responses.

@en

In vivo delivery of siRNA to i ...... es antitumor immune responses.

@nl

type

label

In vivo delivery of siRNA to i ...... es antitumor immune responses.

@en

In vivo delivery of siRNA to i ...... es antitumor immune responses.

@nl

prefLabel

In vivo delivery of siRNA to i ...... es antitumor immune responses.

@en

In vivo delivery of siRNA to i ...... es antitumor immune responses.

@nl

P1433

Q39800142-7F49BF6C-8D52-4655-87CF-877E6EFB5824

P1476

Q39800142-F1883E72-83B6-46B9-B699-D8471E1A314E

P2093

Q39800142-00456210-8392-4D7D-982B-557421A73F21

Q39800142-0E523781-A230-4E73-9EB0-764BDD469FD3

Q39800142-1011D31D-C8F9-4895-BBA4-38CBB99C560D

Q39800142-19B1C4D2-2FEA-421E-8DEF-41A19AC06067

Q39800142-1B8DA299-4B97-411B-A566-CBBA73616C15

Q39800142-1E146E17-33E7-4990-843E-EBE72BF67995

Q39800142-24351F47-AEEE-4632-A06F-B60D38C14EE7

Q39800142-25B9A1B2-A1CB-4A71-9F7F-EFB1F9230052

Q39800142-2E14DA45-6792-4F7E-9FF7-4834FB0284FE

Q39800142-3BADFEBE-1A64-4D18-BF05-DECCC1C7FDAE

P2860

Q39800142-0626E83D-D8EF-47B6-BD37-F75F5BE5975F

Q39800142-072CFEDE-0683-4E65-B6BB-705AA7CDB51A

Q39800142-0B838AC7-29ED-4B88-940A-AE8204CAC493

Q39800142-0D56679E-1CCD-42E9-9058-2B94513452AE

Q39800142-0D67ECEF-AD48-4C4B-B24E-73CDDD51F285

Q39800142-10D2924D-8D48-4FEC-AC09-B7A88DB2378A

Q39800142-1683D100-0C50-405A-A676-60C8D0ACBB63

Q39800142-228C3756-B6EC-4C54-B07A-F3592218F3A9

Q39800142-231E9059-B990-4B88-AB7D-A7CA7936A6EA

Q39800142-2925A8B1-F927-44F5-91E7-96E55C18D476

P2888

Q39800142-0E8FE9A4-8F51-4F6B-89D0-94B514DD8071

P304

Q39800142-10C91EEA-6CD5-4134-9552-4CB466F16704

P31

Q39800142-0223B769-9F5F-4CED-A872-5DF533F213F1

P356

Q39800142-416E179A-330C-4E9B-BE06-BF66506DE5B3

P433

Q39800142-40574B47-D4C9-4D3A-8372-0662CE7F5E55

P478

Q39800142-C6E449FD-EE85-4B3C-85F2-C99583F9C691

P50

Q39800142-115123C5-D3AC-4E9E-B690-C7C43FD04477

P577

Q39800142-5EA9B911-2AD5-49DF-A3BA-95CCD21ED2AD

P5875

Q39800142-D63A6BF8-5BDA-426B-BFBB-80D973EB03E2

P698

Q39800142-6A848D6C-F948-42BB-8171-872182C539B3

P921

Q39800142-6EB834DE-5DE5-4FFB-9284-4E9F76E8696E

P932

Q39800142-86073C16-E2CC-4917-83E6-68E18337C401

P356

P1433

Nature Biotechnology

P1476

In vivo delivery of siRNA to i ...... es antitumor immune responses.

@en

P2093

Andreas Herrmann

http://www.w3.org/2001/XMLSchema#string

Andrew Raubitschek

http://www.w3.org/2001/XMLSchema#string

Anna Scuto

http://www.w3.org/2001/XMLSchema#string

Chunmei Yang

http://www.w3.org/2001/XMLSchema#string

Claudia Kowolik

http://www.w3.org/2001/XMLSchema#string

Drew M Pardoll

http://www.w3.org/2001/XMLSchema#string

Harris S Soifer

http://www.w3.org/2001/XMLSchema#string

Heehyoung Lee

http://www.w3.org/2001/XMLSchema#string

Hua Yu

http://www.w3.org/2001/XMLSchema#string

Jiehui Deng

http://www.w3.org/2001/XMLSchema#string

P2860

A Toll-like receptor recognizes bacterial DNA

TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing

Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors.

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

Functional polarity is introduced by Dicer processing of short substrate RNAs.

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

Toll-like receptor control of the adaptive immune responses

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

The STATs of cancer--new molecular targets come of age

Stat3 as an oncogene

P2888

P304

925-932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.1564

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Raubitschek

P577

2009-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26807857

http://www.w3.org/2001/XMLSchema#string

P698

19749770

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

2846721

http://www.w3.org/2001/XMLSchema#string